Cardiol Therapeutics Inc. (CRDL) vs NervGen Pharma Corp. Common stock (NGEN)
A side-by-side comparison of Cardiol Therapeutics Inc. and NervGen Pharma Corp. Common stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRDL
Cardiol Therapeutics Inc.
$1.31HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
NGEN
NervGen Pharma Corp. Common stock
$1.75HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CRDL vs NGEN
growth of $100 · dividends reinvested · last 1yCRDL +22.2% (+22.2%/yr)NGEN -57.6% (-57.6%/yr)CRDL compounded faster over this window
CRDL NGEN
CRDL vs NGEN: by the numbers
- •CRDL is the larger company ($151M vs $144M market cap).
Metrics side by side
Valuation
| Metric | CRDL | NGEN |
|---|---|---|
| P/B ratio | 8.92 | 11.81 |
Profitability
| Metric | CRDL | NGEN |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -155.34% | -397.38% |
| ROIC | -165.56% | -223.90% |
Growth (annualized)
| Metric | CRDL | NGEN |
|---|---|---|
| Total return CAGR (5Y) | -18.36% | N/A |
Go deeper
Dig into the metrics
Cardiol Therapeutics ROENervGen Pharma Corp. Common stock ROECardiol Therapeutics operating marginNervGen Pharma Corp. Common stock operating marginCardiol Therapeutics revenue growthNervGen Pharma Corp. Common stock revenue growthCardiol Therapeutics free cash flowNervGen Pharma Corp. Common stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.